[New therapeutic approach in glucocorticoid-induce osteoporosis].
Jakob
F
F
Orthopädisches Zentrum für Muskuloskelettale Forschung, Würzburg, Deutschland. f-jakob.klh@uni-wuerzburg.de
Nitschmann
S
S
D019386:Alendronate / Q000009:adverse effects / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D010024:Osteoporosis / Q000139:chemically induced* / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D019379:Teriparatide / Q000009:adverse effects / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D005938:Glucocorticoids; D019379:Teriparatide; D019386:Alendronate